Its success as a therapy lies in the careful, individualized approach to dosing and monitoring, ensuring each patient receives the optimal benefit from treatment
Impressive trial results complex realities Despite the promise of incretin-based therapies, achieving similar outcomes outside of clinical trials has been challenging
Lixisenatide, another GLP-1 analogue, has also been reported to decrease atheroma plaque size and instability in animal models, by reprogramming macrophages towards M2 phenotype (10 g/kg/day) (30)
Semaglutide is FDA-approved for adolescents 12 and older for obesity, and tirzepatide is approved for adolescents 10 and older for Type 2 diabetes
Velocity Clinical Research is currently recruiting participants for a phase 3 clinical trial of retatrutide
A Randomized, Double-Blind, Placebo-Controlled Study of Blend of Herbal Extracts Taken Once Per Day for Weight Loss in Healthy Volunteers